A recent genetic study has provided new insights into how glucagon-like peptide-1 (GLP-1) receptor agonists aid weight loss.

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Diabetes and obesity are growing health concerns worldwide. A type of medication called GLP-1 receptor agonists, commonly ...

(HealthDay News) — For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared with ...

Muscle Preservation: On average, GLP-1 users lose 10% of muscle mass within 1–4 years. Ideal Protein’s high-protein protocol helped participants preserve 95-98% of lean mass during weight loss, ...

A woman from Essex has been awarded £170,000 in compensation from the NHS after developing a crippling addiction to the ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

Biomea Fusion (BMEA) announced that it will feature two oral presentations, one poster presentation, and chair a symposium at the 18th ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic ...